Cedar Realty Trust Series B Cumulative Redeemable Preferred Stock About To Put More Money In Your Pocket

On 5/6/15, Cedar Realty Trust, Inc.'s 7.25% Series B Cumulative Redeemable Preferred Stock (CDR.PRB) will trade ex-dividend, for its quarterly dividend of $0.4531, payable on 5/20/15. As a percentage of CDR.PRB's recent share price of $26.00, this dividend works out to approximately 1.74%, so look for shares of CDR.PRB to trade 1.74% lower — all else being equal — when CDR.PRB shares open for trading on 5/6/15. On an annualized basis, the current yield is approximately 6.96%, which compares to an average yield of 6.93% in the "Real Estate" preferred stock category, according to Preferred Stock Channel.

START SLIDESHOW:
Click here to learn which S.A.F.E. dividend stocks also have preferred shares that should be on your radar screen »

As of last close, CDR.PRB was trading at a 4.12% premium to its liquidation preference amount, versus the average premium of 3.05% in the "Real Estate" category. The chart below shows the one year performance of CDR.PRB shares, versus CDR:

Performance Comparison Chart

Below is a dividend history chart for CDR.PRB, showing historical dividends prior to the most recent $0.4531 on Cedar Realty Trust, Inc.'s 7.25% Series B Cumulative Redeemable Preferred Stock :

CDR.PRB+Dividend+History+Chart

In Monday trading, Cedar Realty Trust, Inc.'s 7.25% Series B Cumulative Redeemable Preferred Stock ( CDR.PRB) is currently down about 0.1% on the day, while the common shares ( CDR) are trading flat.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says